Xiamen Amoytop Biotech Co.Ltd(688278) 3 released the annual performance report on March 30, saying that the operating revenue in 2021 was about 1.132 billion yuan, an increase of 42.61% year-on-year; The net profit attributable to the shareholders of the listed company was about 181 million yuan, an increase of 55.44% year-on-year; The basic earnings per share was 0.45 yuan, a year-on-year increase of 55.17%. It is proposed to distribute a cash dividend of RMB 1 (including tax) for every 10 shares, without conversion to value-added shares or bonus shares.
From January to December 2020, Xiamen Amoytop Biotech Co.Ltd(688278) ‘s operating revenue was composed of biological agents accounting for 99.43%.
Xiamen Amoytop Biotech Co.Ltd(688278) ‘s chairman and general manager are Sun Li, male, 56 years old, with a master’s degree background.
